Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD — Stella

Home/Atopic Dermatitis/Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD

View on ClinicalTrials.gov

Recruiting

Back to Atopic Dermatitis trials

Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

Corvus Clinical Trials, South San Francisco, California

Key details

Phase

Safety & dosing

Sponsor

Corvus Pharmaceuticals, Inc.

Enrollment target

~200 participants

Started

February 2026

Primary completion

June 2027

Age range

18 Years and older

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.